Health News (Reuters)

Novartis wins EU approval for blood cancer therapy Kymriah

Novartis has received European approval for Kymriah, its gene-modifying therapy for blood cancer, but said its introduction would vary from country to country as the Swiss drugmaker works out payment details and builds manufacturing capacity.

Novartis's Kymriah wins EU approval for blood cancer treatment

Novartis received European approval for Kymriah, its gene-modifying therapy for blood cancer, but said its introduction will vary from country to country as the Swiss drugmaker works out payment details and builds manufacturing capacity.

Bayer, J&J's heart drug Xarelto fails trial to widen use

Bayer and Johnson & Johnson's campaign to widen the market for its heart drug Xarelto hit a snag on Sunday when a study for a potential new patient subgroup failed to show a statistically reliant benefit.

Pages